Supplying high quality diagnostics to the microbiome market
Genetic Analysis AS is a researched driven diagnostic company dedicated to deliver new and innovative diagnostic solutions to the rapidly growing human microbiome market
GA has developed and commercialized a standardized diagnostic technology platform for characterization of the human microbiome (GA-map®). Join us in pioneering the field of microbiome diagnostics.
Research and Diagnostics
Want to power your routine lab with CE-marked gut microbiota testing?
Contact GA today. Learn about our CE-marked In Vitro Diagnostic test (GA-map® Dysbiosis Test Lx) for diagnosis and characterizing of dysbiosis in IBS and IBD patients.
Curious about gut microbiota’s role in your field of research?
Contact GA today. Learn more about how you can easily map, study and deep dive in the exciting world of microbiota in a clinical setting.
Want to develop your pharmaceutical product to ensure right patient population and target responders only?
Contact GA today. Learn more about how we can co-develop state-of-the art gut microbiota diagnostics to match your drug profile and make sure your product launch is powered with solid data.
SIGN UP FOR GA’S NEWSLETTER
Great podcast interview with Dr. Michael Ruscio, DNM, DC:
“Understanding the Microbiome with Pioneering Researchers Christina Westby Casén and Anita Patel Jusnes”
Check it out:
GA-map® Dysbiosis Test enables clinicians to quantify a diagnosis of IBS or IBD based on lab markers rather than relying on symptom reporting. This makes it possible to determine appropriate treatment for gut issues with a greater degree of specificity and accuracy than ever before.
Products provided by GA
The GA-map® Dysbiosis Test Lx
Genetic Analysis has developed a CE-marked probe based gut microbiota test on the Luminex® 200 instrument. The technology takes advantage of nucleotide differences in the bacterial 16S rRNA gene to identify predetermined targets.
The GA-map® COVID-19 Fecal Test Kit
The GA-map® COVID-19 Fecal Test is a Qualitative Real Time standardized PCR test for the detection of the 2019 novel coronavirus (SARS-CoV-2) RNA in stool samples and is validated and CE -marked.